Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (ARPEP)
A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Sponsor: Synermore Biologics Co., Ltd.
A PHASE2 clinical study on Rabies, this trial is completed. The trial is conducted by Synermore Biologics Co., Ltd. and has accumulated 11 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Jun 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
-
Sep 2021 — Jun 2022 [monthly]
Active Not Recruiting PHASE2
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Oct 2019 — Aug 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Synermore Biologics Co., Ltd.
- Synermore Biologics USA Limited
For direct contact, visit the study record on ClinicalTrials.gov .